The global IVD market portfolio and associated technologies are constantly evolving. AliveDx utilizes innovative technology that provides more automation and multiplex testing to drive lab workflow efficiency. Our MosaiQ® and LumiQ® solutions are designed to help transform autoimmune and allergy diagnostics performance in clinical settings, supporting productivity gains, while driving cost efficiency in a laboratory setting.
If your lab is reliant on multiple instruments, single plex testing processes or still has fragmented workflows, it could be time to evaluate a lean, efficient in-vitro diagnostic testing solution that supports clinicians in busy lab settings with pressured turnaround times. AliveDx’s multiplex microarray platform offers a streamlined and scalable alternative to legacy solutions. Multiplex testing is an evolution in lab performance that can be quantitatively measured with an non intrusive evaluation, delivering a measurable assessment of what our innovative solutions can do to support lab workflows and diagnostic outputs.
Why your current lab workflow efficiency may need an evaluation
Many labs today face mounting pressure: Increasing test volumes, limited staff time and complex workflows that slow down test to output results. Our MosaiQ and LumiQ solutions are built to directly address common laboratory challenges by:
1 2 Data on file
If your consolidated lab workflow includes multiple instruments that occupy several rooms, it might be time to consider what you could gain from a multiplex microarray solution that can also work in tandem with immunofluorescence (IFA) for a complete turnkey solution.
Quantitative value: What clinical data insights say about our solutions
A European onsite laboratory evaluation revealed significant improvements when adopting MosaiQ and LumiQ solutions:
Turnaround time (TAT)3
Hands-on time4
Instrument efficiency
3 4 Data and calculations available on request
Workflow simplification results in high-throughput testing
AliveDx reduces the need for reflex testing via our MosaiQ solution and simplifies immunofluorescence assay (IFA) processing and reading via our LumiQ solution. The MosaiQ handles solid-phase multiplex testing, while LumiQ automates IFA. Both solutions work independently as standalone instruments, however, when combined they can offer:
Strategic benefits result in productivity gains and lab optimization
Evaluating AliveDx products and solutions has the potential to unlock:
More than a technology upgrade, our solutions are a strategic move toward optimizing operations and improving productivity for higher throughput that increases productivity:
Patients benefit from:
Are you ready for an AliveDx evaluation?
If your lab is interested in reducing lab complexity, saving time, and improving diagnostic accuracy, it could be time for an AliveDx evaluation. Our dedicated team are ready and able to guide you through a tailored assessment that shows in a practical setting how our transformative solutions can transform your lab throughput while delivering measurable value that can positively impact your lab workflow.
Visit us online to learn more:
Visit www.alivedx.com or contact us to speak to an expert and find out more about our solutions. Or you can request your own personalized evaluation.
*Certain assays and intended uses for the MosaiQ® system are currently under development and are not yet cleared by the U.S. Food and Drug Administration. The MosaiQ® instrument is available in the U.S. as a class II 510(k) exempt device.
*LumiQ® is not intended for the US market. This product is not available in the USA, cleared or approved by the U.S. Food and Drug Administration (FDA) for clinical use, currently only available outside of US.
©2025 – AliveDx Suisse SA – AliveDx, AliveDx logo, MosaiQ, AiPlex and MosaiQ AiPlex are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. This study was funded by AliveDx Suisse SA, Eysins, Switzerland. Not all methods may be available in all territories. Subject to regulatory clearance in some territories.
